+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Nsclc Therapeutics"

Global Non-small Cell Lung Cancer Therapeutics Market by Cancer Type (Adenocarcinoma, Large Cell Carcinoma, Squamous Cell Carcinoma), Drug Class (Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Folate Antimetabolites), Distribution Channel - Forecast 2024-2030 - Product Thumbnail Image

Global Non-small Cell Lung Cancer Therapeutics Market by Cancer Type (Adenocarcinoma, Large Cell Carcinoma, Squamous Cell Carcinoma), Drug Class (Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Folate Antimetabolites), Distribution Channel - Forecast 2024-2030

  • Report
  • March 2024
  • 196 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Strategic Business Report

  • Report
  • May 2024
  • 89 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) Pipeline Insight, 2024 - Product Thumbnail Image

Non-Small Cell Lung Cancer (NSCLC) Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Advanced Non-squamous and squamous NSCLC - Pipeline Insight, 2024 - Product Thumbnail Image

Advanced Non-squamous and squamous NSCLC - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
C-Met Mutated Non-small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2024 - Product Thumbnail Image

C-Met Mutated Non-small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Non-Small Cell Lung Cancer (Nsclc): Epidemiology Forecast to 2032 - Product Thumbnail Image

Non-Small Cell Lung Cancer (Nsclc): Epidemiology Forecast to 2032

  • Report
  • February 2024
  • 72 Pages
  • Global
From
Lung Cancer Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Lung Cancer Therapeutics - Global Strategic Business Report

  • Report
  • May 2024
  • 359 Pages
From
United Kingdom Lung Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028 - Product Thumbnail Image

United Kingdom Lung Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028

  • Report
  • October 2023
  • 82 Pages
  • United Kingdom
From
BRAF Mutated Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2030 - Product Thumbnail Image

BRAF Mutated Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2030

  • Report
  • May 2020
  • 100 Pages
  • Global
From
Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC)- Epidemiology Forecast to 2030 - Product Thumbnail Image

Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC)- Epidemiology Forecast to 2030

  • Report
  • May 2020
  • 100 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 - Product Thumbnail Image

Non-Small Cell Lung Cancer (NSCLC) Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

  • Drug Pipelines
  • February 2023
  • 33 Pages
  • Global
From
Non-Small Cell Lung Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape - Product Thumbnail Image

Non-Small Cell Lung Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

  • Report
  • November 2022
  • 164 Pages
  • Global
From
  • 12 Results (Page 1 of 1)
Loading Indicator

The Nsclc Therapeutics market is a subset of the larger Lung Cancer Drugs market. It focuses on the development of treatments for non-small cell lung cancer (NSCLC), the most common type of lung cancer. These treatments include targeted therapies, immunotherapies, and chemotherapy. Targeted therapies are designed to target specific genetic mutations in cancer cells, while immunotherapies use the body's own immune system to fight cancer. Chemotherapy is a traditional form of cancer treatment that uses drugs to kill cancer cells. The Nsclc Therapeutics market is highly competitive, with many companies developing treatments for NSCLC. Some of the major players in the market include AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer, and Roche. Other companies such as AbbVie, Amgen, and Novartis are also active in the market. Show Less Read more